Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 2/20 | 0.40 |
| ▸ | BRAF | P15056 | 3/20 | 0.39 |
| ▸ | KDR | P35968 | 4/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1924164 | 0.90 | MAPT (0.45) | MAPTMEN1KMT2ACASP3TRPV1 | |
| SCHEMBL1924799 | 0.89 | BRAF (0.49) | MAPTMEN1KMT2ATRPV1JAK3 | |
| SCHEMBL1924479 | 0.87 | MAPT (0.55) | MAPTMEN1KMT2ACASP3TRPV1 | |
| SCHEMBL1924936 | 0.86 | PDGFRB (0.49) | RIPK1KDRCA12CA1CA2 | |
| SCHEMBL1924916 | 0.86 | RIPK1 (0.47) | RIPK1MAPTMEN1KMT2APSEN1 | |
| SCHEMBL1924547 | 0.85 | ROCK2 (0.48) | MAPTMEN1KMT2ACASP3TRPV1 | |
| SCHEMBL1925204 | 0.85 | RIPK1 (0.45) | RIPK1MAPTMEN1KMT2AJAK3 | |
| SCHEMBL1924305 | 0.85 | BRAF (0.49) | RIPK1MAPTMEN1KMT2ACASP3 | |
| SCHEMBL1925485 | 0.84 | MEN1 (0.43) | MAPTMEN1KMT2ACASP3TRPV1 | |
| SCHEMBL1924062 | 0.84 | BRAF (0.48) | MAPTMEN1KMT2ACASP3TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1856043-B1 | 1-H-PYRROLE-2-CARBOXAMIDES AND IMIDAZOLE-5-CARBOXAMIDES AND USE THEREOF AS FAK, KDR AND TIE2 KINASE MODULATORS FOR THE TREATMENT OF CANCER | AVENTIS PHARMA SA (FR) | 2011-06-08 | — | — | EP | claimed |
| US-7560571-B2 | Substituted pyrroles and imidazoles, compositions containing same, manufacturing process therefor and use thereof | AVENTIS PHARMA S.A. (FR) | 2009-07-14 | — | — | US | claimed |
| US-20080045542-A1 | Substituted Pyrroles and Imidazoles, Compositions Containing Same, Manufacturing Process Therefor and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-02-21 | — | — | US | claimed |
| US-7560571-B2 | Substituted pyrroles and imidazoles, compositions containing same, manufacturing process therefor and use thereof | AVENTIS PHARMA S.A. (FR) | 2009-07-14 | — | — | US | disclosed |
| US-7560571-B2 | Substituted pyrroles and imidazoles, compositions containing same, manufacturing process therefor and use thereof | AVENTIS PHARMA S.A. (FR) | 2009-07-14 | — | — | US | disclosed |
| US-7560571-B2 | Substituted pyrroles and imidazoles, compositions containing same, manufacturing process therefor and use thereof | AVENTIS PHARMA S.A. (FR) | 2009-07-14 | — | — | US | disclosed |
| US-20080045542-A1 | Substituted Pyrroles and Imidazoles, Compositions Containing Same, Manufacturing Process Therefor and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-02-21 | — | — | US | disclosed |
| US-20080045542-A1 | Substituted Pyrroles and Imidazoles, Compositions Containing Same, Manufacturing Process Therefor and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-02-21 | — | — | US | disclosed |
| US-20080045542-A1 | Substituted Pyrroles and Imidazoles, Compositions Containing Same, Manufacturing Process Therefor and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045542-A1 | Substituted Pyrroles and Imidazoles, Compositions Containing Same, Manufacturing Process Therefor and Use Thereof | WEE1, WEE2, FARS2 | RIPK1 2273/4885MAPT 1988/4885MEN1 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.